Also known as: neovascular AMD
Recent studies on metformin and age-related macular degeneration report conflicting findings: a JAMA Ophthalmology cohort found no association, while studies in Ophthalmology Retina and BMJ Open Ophthalmology found reduced odds of neovascular and intermediate AMD, respectively. All were observational.
Biocon's Yesafili, an interchangeable aflibercept biosimilar, is now available in the U.S., while Zydus Lifesciences launched Anyra in India. Both aim to treat retinal diseases such as diabetic macular edema. Biocon plans further launches in the UK and other markets, as competition intensifies.
Immune checkpoint inhibitors are associated with a significantly lower risk of non-neovascular age-related macular degeneration, while sociodemographic disparities strongly influence diabetic retinopathy screening adherence, according to two separate ophthalmology studies.
AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07614776 |
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration |
RECRUITING | PHASE3 |
| NCT07007065 |
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
RECRUITING | PHASE3 |
| NCT06847542 |
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD |
RECRUITING | PHASE3 |
| NCT06680817 |
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) |
ACTIVE_NOT_RECRUITING | |
| NCT06660667 |
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06439576 |
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) |
ACTIVE_NOT_RECRUITING | |
| NCT06190093 |
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) |
COMPLETED | PHASE3 |
| NCT05904028 |
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05562947 |
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) |
RECRUITING | PHASE3 |
| NCT05476926 |
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products |
ACTIVE_NOT_RECRUITING |
